H2-receptor antagonists

Ibuprofen and Famotidine

Approved 18 Mar 2024OralTablet

The FDA lists this product in 7 strengths and forms.

Official labelAsk Osler about it

Composition

Active ingredients: FAMOTIDINE 26.6MG; IBUPROFEN 800MG

Strengths and forms

The FDA lists each strength of a product separately; these pages share one label.

Official product information

Drugs@FDA lists the approved labels, letters and reviews for application ANDA215925.

Open Drugs@FDA

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Brand name: Ibuprofen and Famotidine
Active substance: famotidine
Drug class: H2-receptor antagonists
Group: Acid suppressants
Route: Oral
Dosage form: Tablet
Applicant: Torrent
Status: Discontinued
FDA approval: 18 Mar 2024
Application: ANDA215925-001
RxCUI: 4278

Guidelines

FDA 2020

Pantoprazole SodiumFor suspension, delayed release

Esomeprazole MagnesiumFor suspension, delayed release

OmeprazoleTablet, orally disintegrating, delayed release

DexlansoprazoleCapsule, delayed release

Nexium 24HResomeprazole magnesium · Tablet, delayed release

Omeprazole MagnesiumTablet, delayed release

Rabeprazole SodiumTablet, delayed release

Omeprazole and Sodium Bicarbonateomeprazole · For suspension

Esomeprazole SodiumInjectable

Duexisfamotidine · Tablet

LansoprazoleTablet, orally disintegrating, delayed release

FamotidineFor suspension

Zegerid OTComeprazole · Capsule

NizatidineSolution

Dexilantdexlansoprazole · Capsule, delayed release